Home > Resources > Whitepapers > Genetic Engineering and Environmental Risk

Genetic Engineering and Environmental Risk

January 10, 2018

Genetic engineering in today’s world is gaining much importance. It provides plant varieties with good agronomic characteristics, superior quality values and expressing traits of agricultural interest such as insect resistance and herbicide tolerance. The production and use of genetically modified organisms (GMO’s) are increasing steadily. There are various techniques by which genetically modified crops can be developed. But the issue still remains; whether altering the genetic structure of any organism is ethical, will it create any problem for the people who consume it.

Spotlight

IZiel Healthcare

IZiel Healthcare is a Global Engineering Services company providing complete solutions in product development and management to medical device companies. We leverage statistical & data driven methods, domain knowledge & robust work planning methodology to achieve an optimized product development processes for guaranteed success.

OTHER WHITEPAPERS

2022 Biosimilars Report: The U.S. Journey and Path Ahead

whitePaper | June 8, 2022

Cardinal Health is fortunate to sit at the crossroads of the United States (U.S.) healthcare system, engaging with stakeholders from across the industry including healthcare

Asia Pacific Leads The Way In Cell & Gene Therapy Trials

whitePaper | December 16, 2022

Cell and gene therapies (CGTs) are continuing to gain momentum in life sciences globally. However, Asia Pacific (APAC) has demonstrated the most growth in CGT developers of any other region, with a rise of 10% in H1 2022 compared to 2021.1

T Cell Expansion in Small Scale Bioreactors

whitePaper | October 28, 2022

Adoptive cell therapy (ACT), a branch of immunotherapy, offers a promising treatment for chronic viral infections and malignant diseases such as cancer [1]. This innovative approach involves the autologous or allogenic transplant of immune cells into the patient’s body.

The affordability hurdle for gene therapies

whitePaper | October 12, 2022

Advanced therapy medicinal products cell and gene therapies offer tremendous hope for patients either by actually curing serious diseases or by alleviating suffering.

Multi-Specific Monoclonal Antibodies

whitePaper | February 22, 2023

The reason for the rapid expansion and development of the therapeutic antibody sector is the capacity of monoclonal antibodies to precisely bind a target antigen and neutralise or promote its activity. The efficacy and safety.

The US Bioeconomy

whitePaper | April 14, 2022

In the nearly 50 years since the first genetic engineering experiments, the United States has become the world’s biotechnology powerhouse,